Navigation Links
Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) announced today that Lewis H. Bender, Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at 11:35 am EST. The conference will be held at the New York Palace Hotel in New York.

A live audio webcast of the presentation will be available on the Events section of the Interleukin Genetics website, http://www.ilgenetics.com/content/about-interleukin/events.jsp. A replay of the presentation will be available on the Company's website for 14 days following the presentation.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin-12 indicates survival prospects for melanoma patients
2. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
3. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
4. T cell immunity enhanced by timing of interleukin-7 therapy
5. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
6. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
7. DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results
8. Genetics, Environment Shape Sexual Behavior
9. Homosexual behavior due to genetics and environmental factors
10. 2008 Gruber Genetics Prize awarded to Allan Spradling of Carnegie Institution
11. 6 Nobel Prize Winners at International Congress of Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: